Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Stevens-Johnson Syndrome (SJS) is an infrequent yet severe mucocutaneous reaction that involves less than 10% of the Body Surface Area (BSA). It is predominantly induced by certain medications, including anticonvulsants (., Lamotrigine, Carbamazepine, Phenytoin, Phenobarbitone), Allopurinol at doses above 100 mg per day, and sulphonamides (., Cotrimoxazole, Sulfasalazine). Genetic predispositions, particularly the presence of the HLA-B*1502 allele, significantly increase the risk of developing SJS. This case report discusses a unique presentation of SJS in a young female patient, emphasizing the critical need for genetic screening and careful monitoring when prescribing Carbamazepine, especially in populations at higher genetic risk.

Case Presentation

A 19-year-old female patient, who had been on Phenytoin and Sodium Valproate for epilepsy management over the past year, was newly prescribed Carbamazepine. Within a week of initiating Carbamazepine, the patient experienced a seizure, followed by the sudden onset of fever, painful sores, and blisters covering the upper body, along with mucous discharge from both eyes. These symptoms rapidly worsened. Based on clinical presentations and the extent of epidermal detachment, the patient was diagnosed with SJS. The severity and mortality risks were assessed using the SCORTEN score. Therapeutic interventions included intravenous Ranitidine, Ondansetron, Paracetamol, Midazolam, Levetiracetam, and Dexamethasone, along with oral Fluconazole, Chlorpheniramine tablets, and Ciprofloxacin eye drops. The patient showed significant improvement and was discharged after fourteen days with follow-up advice.

Conclusion

This case underscores the critical importance of performing genetic testing for the HLA-B*1502 allele and conducting baseline blood tests before initiating Carbamazepine therapy. Such precautionary measures can significantly mitigate the risk of severe adverse reactions like SJS. This report adds to the scientific literature by highlighting the potential dangers associated with anticonvulsant therapies and the necessity for personalized medicine approaches in preventing life-threatening conditions. The main takeaway is the pivotal role of genetic screening and vigilant monitoring in the management of patients requiring anticonvulsant medications to prevent serious adverse reactions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863328893241018101435
2024-11-05
2025-07-25

  • From This Site

    /content/journals/cds/10.2174/0115748863328893241018101435
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FrenchL.E. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.Allergol. Int.200655191610.2332/allergolint.55.9 17075281
     [Google Scholar]
  2. LerchM. MainettiC. Terziroli Beretta-PiccoliB. HarrT. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Clin. Rev. Allergy Immunol.201854114717610.1007/s12016‑017‑8654‑z 29188475
     [Google Scholar]
  3. ShresthaA.B. ShresthaS. YadavP.K. AdhikariL. YadavA. Cefixime induced Steven Johnson syndrome: A case report from Bangladesh.Ann. Med. Surg. (Lond.)20227910408910.1016/j.amsu.2022.104089 35860067
     [Google Scholar]
  4. AquinoM. RosnerG. Systemic Contact Dermatitis.Clin. Rev. Allergy Immunol.201956191810.1007/s12016‑018‑8686‑z 29766368
     [Google Scholar]
  5. ChangB.L. LiuJ.R. ChangS.H. SeeL.C. Impact on carbamazepine usage and cutaneous adverse reactions before and after the reimbursement of HLA‐B*1502 genotyping in Taiwan, 2000-2017: A nationwide longitudinal study.Epilepsia202364102679268910.1111/epi.17726 37506179
     [Google Scholar]
  6. YangS.C. HuS. ZhangS.Z. Corrigendum to “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China”.J. Immunol. Res.201820181310.1155/2018/4154507 30050956
     [Google Scholar]
  7. FreyN. JossiJ. BodmerM. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK.J. Invest. Dermatol.201713761240124710.1016/j.jid.2017.01.031 28202399
     [Google Scholar]
  8. WasuwanichP. SoJ.M. ChakralaT.S. ChenJ. MotaparthiK. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome.JAAD Int.202313172510.1016/j.jdin.2023.06.014 37575514
     [Google Scholar]
  9. SuS.C. MockenhauptM. WolkensteinP. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.J. Invest. Dermatol.201713751065107310.1016/j.jid.2016.11.034 28011147
     [Google Scholar]
  10. ChungW.H. WangC.W. DaoR.L. Severe cutaneous adverse drug reactions.J. Dermatol.201643775876610.1111/1346‑8138.13430 27154258
     [Google Scholar]
  11. StrużynaJ. SurowieckaA. KorzeniowskiT. Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis.BMC Med. Inform. Decis. Mak.202222127310.1186/s12911‑022‑02013‑2 36261833
     [Google Scholar]
  12. IbarretaD. EllesR. CassimanJ.J. Rodriguez-CerezoE. DequekerE. Towards quality assurance and harmonization of genetic testing services in the European Union.Nat. Biotechnol.200422101230123510.1038/nbt1004‑1230 15470457
     [Google Scholar]
  13. PoupětováH. LedvinováJ. BernáL. DvořákováL. KožichV. EllederM. The birth prevalence of lysosomal storage disorders in the Czech Republic: Comparison with data in different populations.J. Inherit. Metab. Dis.201033438739610.1007/s10545‑010‑9093‑7 20490927
     [Google Scholar]
  14. FakoyaA.O.J. OmenyiP. AnthonyP. Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.Open Access Maced. J. Med. Sci.20186473073810.3889/oamjms.2018.148 29731949
     [Google Scholar]
  15. ChungW.H. HungS.I. HongH.S. A marker for Stevens-Johnson syndrome.Nature2004428698248610.1038/428486a 15057820
     [Google Scholar]
  16. FunanageV.L. Impact of Genetic Testing on Human Health.Del. J. Public Health202175101110.32481/djph.2021.12.005 35619978
     [Google Scholar]
  17. KatsanisS.H. KatsanisN. Molecular genetic testing and the future of clinical genomics.Nat. Rev. Genet.201314641542610.1038/nrg3493 23681062
     [Google Scholar]
  18. LeeE. KnoxC. PhillipsE. Prevalence of antibiotic-induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): A systematic review and meta-analysis.J. Allergy Clin. Immunol.20231512AB5710.1016/j.jaci.2022.12.182
     [Google Scholar]
  19. SinghN. PhillipsM. Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches.Skin Therapy Lett.2022275713 36469487
     [Google Scholar]
  20. ZimmermanD. DangN.H. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). In: Oncologic Critical Care.ChamSpringer International Publishing202026728010.1007/978‑3‑319‑74588‑6_195
     [Google Scholar]
  21. MockenhauptM. Stevens-John syndrome and toxic epidermal necrolysis: Clinical patterns, diagnostic considerations, etiology, and therapeutic management.Semin. Cutan. Med. Surg.2014331101610.12788/j.sder.0058 25037254
     [Google Scholar]
  22. SchwartzR.A. McDonoughP.H. LeeB.W. Toxic epidermal necrolysis.J. Am. Acad. Dermatol.2013692173.e1173.e1310.1016/j.jaad.2013.05.003 23866878
     [Google Scholar]
  23. LocharernkulC. ShotelersukV. HirankarnN. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions.J. Clin. Neurosci.201118101289129410.1016/j.jocn.2010.12.054 21802305
     [Google Scholar]
  24. McCormackM. AlfirevicA. BourgeoisS. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.N. Engl. J. Med.2011364121134114310.1056/NEJMoa1013297 21428769
     [Google Scholar]
  25. NasirS.A. TanH.L. TanH.J. HussainiH.M. RamliR. Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription.Case Rep. Dent.201720171510.1155/2017/4201357 28473929
     [Google Scholar]
  26. RoujeauJ.C. SternR.S. Severe adverse cutaneous reactions to drugs.N. Engl. J. Med.1994331191272128510.1056/NEJM199411103311906 7794310
     [Google Scholar]
  27. NoeM.H. MichelettiR.G. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.Clin. Dermatol.202038660761210.1016/j.clindermatol.2020.06.016 33341195
     [Google Scholar]
  28. CefaluJ.E. BarrierK.M. DavisA.H. Wound Infections in Critical Care.Crit. Care Nurs. Clin. North Am.2017291819610.1016/j.cnc.2016.09.009 28160959
     [Google Scholar]
  29. LiangS.Y. TheodoroD.L. SchuurJ.D. MarschallJ. Infection prevention in the emergency department.Ann. Emerg. Med.201464329931310.1016/j.annemergmed.2014.02.024 24721718
     [Google Scholar]
  30. LeH.G. SaeedH. MantagosI.S. MitchellC.M. GovermanJ. ChodoshJ. Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey.Burns201642483083510.1016/j.burns.2015.12.001 26810444
     [Google Scholar]
  31. WallV. YenM.T. YangM.E.I-C.H.U.A.N. HuangA.J.W. PflugfelderS.C. Management of the late ocular sequelae of Stevens-Johnson syndrome.Ocul. Surf.20031419220110.1016/S1542‑0124(12)70014‑9 17075650
     [Google Scholar]
  32. SchneiderJ.A. CohenP.R. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.Adv. Ther.20173461235124410.1007/s12325‑017‑0530‑y 28439852
     [Google Scholar]
  33. CreamerD. WalshS.A. DziewulskiP. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.J. Plast. Reconstr. Aesthet. Surg.201669673674110.1016/j.bjps.2016.04.018 27216885
     [Google Scholar]
  34. XuL.Q. ZhaoX.X. WangP.X. YangJ. YangY.M. Multidisciplinary treatment of a patient with necrotizing fasciitis caused by Staphylococcus aureus: A case report.World J. Clin. Cases20197213595360210.12998/wjcc.v7.i21.3595 31750343
     [Google Scholar]
  35. FranksA.G.Jr Skin manifestations of internal disease.Med. Clin. North Am.20099361265128210.1016/j.mcna.2009.08.010 19932330
     [Google Scholar]
  36. WoolumJ.A. BaileyA.M. BaumR.A. MettsE.L. A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Adv. Emerg. Nurs. J.2019411566410.1097/TME.0000000000000225 30702535
     [Google Scholar]
  37. ShanbhagS.S. ChodoshJ. FathyC. GovermanJ. MitchellC. SaeedH.N. Multidisciplinary care in Stevens-Johnson syndrome.Ther. Adv. Chronic Dis.20201110.1177/2040622319894469 32523661
     [Google Scholar]
  38. WojtkiewiczA. WysockiM. FortunaJ. ChrupekM. MatczukM. KoltanA. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis.Acta Derm. Venereol.200888442042110.2340/00015555‑0462 18709327
     [Google Scholar]
  39. PatmanidisK. SidirasA. DolianitisK. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: Successful treatment of an elderly patient.Case Rep. Dermatol. Med.201220121310.1155/2012/915314 23259092
     [Google Scholar]
  40. Zárate-CorreaL.C. Carrillo-GómezD.C. Ramírez-EscobarA.F. Serrano-ReyesC. Toxic epidermal necrolysis successfully treated with infliximab.J. Investig. Allergol. Clin. Immunol.20132316163 23653980
     [Google Scholar]
  41. KirchhofM.G. MiliszewskiM.A. SikoraS. PappA. DutzJ.P. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.J. Am. Acad. Dermatol.201471594194710.1016/j.jaad.2014.07.016 25087214
     [Google Scholar]
  42. KumarP. Kanti DasN. Cyclosporine in toxic epidermal necrolysis: A brief review of the emerging therapeutic modality.Dermatol. Online J.201622102210.5070/D32210032890 28329582
     [Google Scholar]
  43. DorafsharA.H. DickieS.R. CohnA.B. Antishear therapy for toxic epidermal necrolysis: An alternative treatment approach.Plast. Reconstr. Surg.2008122115416010.1097/PRS.0b013e3181773d5d 18594400
     [Google Scholar]
  44. AbuzneidY.S. AlzeerelhouseiniH.I.A. RabiD. Carbamazepine Induced Stevens-Johnson Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the Literature.Case Rep. Dermatol. Med.202220221410.1155/2022/6128688 35572158
     [Google Scholar]
  45. OliveiraA. SanchesM. SeloresM. Stevens-Johnson syndrome and toxic epidermal necrolysis.Acta Med. Port.2011249951002 22863510
     [Google Scholar]
  46. FouchardN. BertocchiM. RoujeauJ-C. RevuzJ. WolkensteinP. Bastuji-GarinS. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis.J. Invest. Dermatol.2000115214915310.1046/j.1523‑1747.2000.00061.x 10951229
     [Google Scholar]
  47. HernanR. ChoM.T. WilsonA.L. Impact of patient education videos on genetic counseling outcomes after exome sequencing.Patient Educ. Couns.2020103112713510.1016/j.pec.2019.08.018 31521424
     [Google Scholar]
  48. de OlazarraA.S. WangS.X. Advances in point-of-care genetic testing for personalized medicine applications.Biomicrofluidics202317303150110.1063/5.0143311 37159750
     [Google Scholar]
/content/journals/cds/10.2174/0115748863328893241018101435
Loading
Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature
Curr Drug Saf 20, 382 (2025); https://doi.org/10.2174/0115748863328893241018101435
/content/journals/cds/10.2174/0115748863328893241018101435
/content/journals/cds/10.2174/0115748863328893241018101435
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): anticonvulsant; Carbamazepine; genetic testing; HLA-B*1502; seizure; stevens-johnson syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test